{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:45Z","timestamp":1794047445985,"version":"4.8.0"},"reference-count":46,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"11","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Post-transplant lymphoproliferative disorders (PTLD) are iatrogenic immune deficiency-associated lymphoid\/plasmacytic proliferations developing due to immunosuppression in solid organ or hematopoietic stem cell allograft patients. PTLD are characterized by abnormal proliferation of lymphoid cells and have a heterogeneous clinical behavior. We profiled expression of &gt;700 tumor microenvironment (TME)-related genes in 75 post-transplant aggressive B-cell lymphomas (PTABCL). Epstein-Barr virus (EBV)-positive PT-ABCL clustered together and were enriched for type I interferon pathway and antiviral-response genes. Additionally, a cytotoxicity gene signature associated with EBV-positivity and favorable overall survival (OS) (hazard ratio =0.61; P=0.019). In silico immunophenotyping revealed two subgroups with distinct immune cell compositions. The inflamed subgroup with higher proportions of immune cells had better outcome compared to noninflamed subgroup (median OS &gt;200.0 vs. 15.2 months; P=0.006). In multivariable analysis with EBV status, International Prognostic Index, and rituximab-containing treatment, inflamed TME remained as an independent predictor for favorable outcome. We also compared TME between post-transplant and immunocompetent host diffuse large B-cell lymphomas (n=75) and discovered that the proportions of T cells were lower in PT-diffuse large B-cell lymphomas. In conclusion, we provide a comprehensive phenotypic characterization of PT-ABCL, highlighting the importance of immune cell composition of TME in determining the clinical behavior and prognosis of PT-ABCL.<\/jats:p>","DOI":"10.3324\/haematol.2023.282831","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T03:32:23Z","timestamp":1685590343000},"page":"3044-3057","source":"Crossref","is-referenced-by-count":5,"title":["Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas"],"prefix":"10.3324","volume":"108","author":[{"given":"Suvi-Katri","family":"Leivonen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terhi","family":"Friman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias","family":"Autio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuli","family":"Vaittinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas Wind","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"D\u2019Amore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Jacques","family":"Hamilton-Dutoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Holte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Beiske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panu E.","family":"Kovanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka","family":"R\u00e4ty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirpa","family":"Lepp\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"key":"53759","doi-asserted-by":"crossref","unstructured":"Friman TK, Jaamaa-Holmberg S, Aberg F. Cancer risk and mortality after solid organ transplantation: a population-based 30-year cohort study in Finland. Int J Cancer. 2022; 150(11):1779-1791.","DOI":"10.1002\/ijc.33934"},{"key":"53760","doi-asserted-by":"crossref","unstructured":"Alaggio R, Amador C, Anagnostopoulos I. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748.","DOI":"10.1038\/s41375-022-01625-x"},{"key":"53761","doi-asserted-by":"crossref","unstructured":"Campo E, Jaffe ES, Cook JR. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022; 140(11):1229-1253.","DOI":"10.1182\/blood.2022015851"},{"key":"53762","doi-asserted-by":"crossref","unstructured":"Swerdlow SH, Campo E, Pileri SA. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375-2390.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"53763","doi-asserted-by":"crossref","unstructured":"Crombie JL, LaCasce AS. Epstein Barr virus associated B-cell lymphomas and Iatrogenic lymphoproliferative disorders. Front Oncol. 2019; 9:109.","DOI":"10.3389\/fonc.2019.00109"},{"key":"53764","doi-asserted-by":"crossref","unstructured":"Dierickx D, Tousseyn T, Gheysens O. How I treat posttransplant lymphoproliferative disorders. Blood. 2015; 126(20):2274-2283.","DOI":"10.1182\/blood-2015-05-615872"},{"key":"53765","doi-asserted-by":"crossref","unstructured":"Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults. N Engl J Med. 2018; 378(6):549-562.","DOI":"10.1056\/NEJMra1702693"},{"key":"53766","doi-asserted-by":"crossref","unstructured":"Ferla V, Rossi FG, Goldaniga MC, Baldini L. Biological difference between Epstein-Barr virus positive and negative post-transplant lymphoproliferative disorders and their clinical impact. Front Oncol. 2020; 10:506.","DOI":"10.3389\/fonc.2020.00506"},{"key":"53767","doi-asserted-by":"crossref","unstructured":"Morscio J, Dierickx D, Ferreiro JF. Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Am J Transplant. 2013; 13(5):1305-1316.","DOI":"10.1111\/ajt.12196"},{"key":"53768","doi-asserted-by":"crossref","unstructured":"Craig FE, Johnson LR, Harvey SA. Gene expression profiling of Epstein-Barr virus-positive and -negative monomorphic B-cell posttransplant lymphoproliferative disorders. Diagn Mol Pathol. 2007; 16(3):158-168.","DOI":"10.1097\/PDM.0b013e31804f54a9"},{"key":"53769","doi-asserted-by":"crossref","unstructured":"Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 2014; 14(8):517-534.","DOI":"10.1038\/nrc3774"},{"key":"53770","doi-asserted-by":"crossref","unstructured":"Marcelis L, Tousseyn T. The tumor microenvironment in post-transplant lymphoproliferative disorders. Cancer Microenviron. 2019; 12(1):3-16.","DOI":"10.1007\/s12307-018-00219-5"},{"key":"53771","doi-asserted-by":"crossref","unstructured":"Holte H, Leppa S, Bjorkholm M. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell\/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol. 2013; 24(5):1385-1392.","DOI":"10.1093\/annonc\/mds621"},{"key":"53772","doi-asserted-by":"crossref","unstructured":"Leppa S, Jorgensen J, Tierens A. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. Blood Adv. 2020; 4(9):1906-1915.","DOI":"10.1182\/bloodadvances.2020001518"},{"key":"53773","doi-asserted-by":"crossref","unstructured":"Autio M, Leivonen SK, Bruck O. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. Haematologica. 2021; 106(3):718-729.","DOI":"10.3324\/haematol.2019.243626"},{"key":"53774","doi-asserted-by":"crossref","unstructured":"Newman AM, Liu CL, Green MR. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-457.","DOI":"10.1038\/nmeth.3337"},{"key":"53775","doi-asserted-by":"crossref","unstructured":"Newman AM, Steen CB, Liu CL. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019; 37(7):773-782.","DOI":"10.1038\/s41587-019-0114-2"},{"key":"53776","doi-asserted-by":"crossref","unstructured":"Dave SS, Fu K, Wright GW. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006; 354(23):2431-2442.","DOI":"10.1056\/NEJMoa055759"},{"key":"53777","doi-asserted-by":"crossref","unstructured":"Montesinos-Rongen M, Brunn A, Bentink S. Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell. Leukemia. 2008; 22(2):400-405.","DOI":"10.1038\/sj.leu.2405019"},{"key":"53778","doi-asserted-by":"crossref","unstructured":"Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017; 35(21):2410-2418.","DOI":"10.1200\/JCO.2017.72.7602"},{"key":"53779","doi-asserted-by":"crossref","unstructured":"Bollard CM, Rooney CM, Heslop HE. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol. 2012; 9(9):510-519.","DOI":"10.1038\/nrclinonc.2012.111"},{"key":"53780","doi-asserted-by":"crossref","unstructured":"Morscio J, Finalet Ferreiro J, Vander Borght S. Identification of distinct subgroups of EBV-positive post-transplant diffuse large B-cell lymphoma. Mod Pathol. 2017; 30(3):370-381.","DOI":"10.1038\/modpathol.2016.199"},{"key":"53781","doi-asserted-by":"crossref","unstructured":"Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE. Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol. 2001; 19(3):720-726.","DOI":"10.1200\/JCO.2001.19.3.720"},{"key":"53782","doi-asserted-by":"crossref","unstructured":"Keane C, Gill D, Vari F, Cross D, Griffiths L, Gandhi M. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy. Am J Hematol. 2013; 88(4):273-276.","DOI":"10.1002\/ajh.23398"},{"key":"53783","doi-asserted-by":"crossref","unstructured":"Keane C, Vari F, Hertzberg M. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Lancet Haematol. 2015; 2(10):e445-455.","DOI":"10.1016\/S2352-3026(15)00150-7"},{"key":"53784","doi-asserted-by":"crossref","unstructured":"Autio M, Leivonen SK, Bruck O, Karjalainen-Lindsberg ML, Pellinen T, Leppa S. Clinical impact of immune cells and their spatial interactions in diffuse large B-cell lymphoma microenvironment. Clin Cancer Res. 2022; 28(4):781-792.","DOI":"10.1158\/1078-0432.CCR-21-3140"},{"key":"53785","doi-asserted-by":"crossref","unstructured":"Leivonen SK, Pollari M, Bruck O. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. Haematologica. 2019; 104(2):338-346.","DOI":"10.3324\/haematol.2018.200105"},{"key":"53786","doi-asserted-by":"crossref","unstructured":"Schroers-Martin J, Garofalo A, Soo J. Tumor microenvironment determinants of immunotherapy response identified by integrated host &amp; viral analysis of post-transplant lymphoproliferative disorders. Blood. 2022; 140(Suppl 1):S172-174.","DOI":"10.1182\/blood-2022-158647"},{"key":"53787","doi-asserted-by":"crossref","unstructured":"Sehn LH, Hertzberg M, Opat S. Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022; 6(2):533-543.","DOI":"10.1182\/bloodadvances.2021005794"},{"key":"53788","doi-asserted-by":"crossref","unstructured":"Tilly H, Morschhauser F, Sehn LH. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022; 386(4):351-363.","DOI":"10.1056\/NEJMoa2115304"},{"key":"53789","doi-asserted-by":"crossref","unstructured":"Sehn LH, Herrera AF, Flowers CR. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020; 38(2):155-165.","DOI":"10.1200\/JCO.19.00172"},{"key":"53790","doi-asserted-by":"crossref","unstructured":"Delgado J, Papadouli I, Sarac SB. The European Medicines Agency review of tafasitamab in combination with lenalidomide for the treatment of adult patients with relapsed\/refractory diffuse large B-cell lymphoma. Hemasphere. 2021; 5(12):e666.","DOI":"10.1097\/HS9.0000000000000666"},{"key":"53791","doi-asserted-by":"crossref","unstructured":"Nowakowski GS, Yoon DH, Peters A. Improved efficacy of tafasitamab plus lenalidomide versus systemic therapies for relapsed\/refractory DLBCL: RE-MIND2, an observational retrospective matched cohort study. Clin Cancer Res. 2022; 28(18):4003-4017.","DOI":"10.1158\/1078-0432.CCR-21-3648"},{"key":"53792","doi-asserted-by":"crossref","unstructured":"Salles G, Duell J, Gonzalez Barca E. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020; 21(7):978-988.","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"53793","doi-asserted-by":"crossref","unstructured":"Friedberg JW, Sharman J, Sweetenham J. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010; 115(13):2578-2585.","DOI":"10.1182\/blood-2009-08-236471"},{"key":"53794","doi-asserted-by":"crossref","unstructured":"Flinn IW, Bartlett NL, Blum KA. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Eur J Cancer. 2016; 54:11-17.","DOI":"10.1016\/j.ejca.2015.10.005"},{"key":"53795","doi-asserted-by":"crossref","unstructured":"Ferreiro JF, Morscio J, Dierickx D. EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcriptomic features. Am J Transplant. 2016; 16(2):414-425.","DOI":"10.1111\/ajt.13558"},{"key":"53796","doi-asserted-by":"crossref","unstructured":"Luskin MR, Heil DS, Tan KS. The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder. Am J Transplant. 2015; 15(10):2665-2673.","DOI":"10.1111\/ajt.13324"},{"key":"53797","doi-asserted-by":"crossref","unstructured":"Evens AM, David KA, Helenowski I. Multicenter analysis of 80 solid organ transplantation recipients with posttransplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010; 28(6):1038-1046.","DOI":"10.1200\/JCO.2009.25.4961"},{"key":"53798","doi-asserted-by":"crossref","unstructured":"Ghobrial IM, Habermann TM, Maurer MJ. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol. 2005; 23(30):7574-7582.","DOI":"10.1200\/JCO.2005.01.0934"},{"key":"53799","doi-asserted-by":"crossref","unstructured":"Menter T, Juskevicius D, Alikian M. Mutational landscape of B-cell post-transplant lymphoproliferative disorders. Br J Haematol. 2017; 178(1):48-56.","DOI":"10.1111\/bjh.14633"},{"key":"53800","doi-asserted-by":"crossref","unstructured":"Kotlov N, Bagaev A, Revuelta MV. Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures. Cancer Discov. 2021; 11(6):1468-1489.","DOI":"10.1158\/2159-8290.CD-20-0839"},{"key":"53801","doi-asserted-by":"crossref","unstructured":"Lenz G, Wright G, Dave SS. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008; 359(22):2313-2323.","DOI":"10.1056\/NEJMoa0802885"},{"key":"53802","doi-asserted-by":"crossref","unstructured":"Monti S, Savage KJ, Kutok JL. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005; 105(5):1851-1861.","DOI":"10.1182\/blood-2004-07-2947"},{"key":"53803","doi-asserted-by":"crossref","unstructured":"Trappe RU, Dierickx D, Zimmermann H. Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial. J Clin Oncol. 2017; 35(5):536-543.","DOI":"10.1200\/JCO.2016.69.3564"},{"key":"53804","doi-asserted-by":"crossref","unstructured":"Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004; 4(2):222-230.","DOI":"10.1046\/j.1600-6143.2003.00325.x"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282831\/75691","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282831\/76227","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11104\/75691","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:10Z","timestamp":1794045850000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.282831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":46,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.282831","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,1]]}}}